Hartmann's Solution

Adult administration

For adults, a single intravenous drip infusion of 500 to 1,000mL is administered. The infusion rate should be no more than 0.5g per kg body weight per hour as dextrose. The dosage and infusion rate should be adjusted appropriately according to age, weight, and symptoms.

This medication contains dextrose, which can increase the consumption of vitamin B1 (thiamine) in the body during intravenous administration, so caution is required. This medication contains calcium, which can cause precipitation when used with certain antibiotics like ceftriaxone, therefore it should not be administered simultaneously via the same infusion apparatus. When using this medication, allergic reactions or hypersensitivity reactions such as anaphylaxis may occur, so if unusual symptoms arise, administration should be stopped immediately and appropriate treatment should be provided. As this solution contains potassium, patients with impaired kidney function or heart disease may have an increased risk of hyperkalemia, and periodic monitoring of serum potassium levels is necessary. Due to the presence of dextrose, administration to patients with impaired glucose tolerance could result in a rapid increase in blood sugar, necessitating frequent blood sugar checks and consideration of insulin administration if needed. Sodium and chloride ions are included, which can cause hypernatremia or hyperchloremia, and caution is required in patients at risk of fluid overload. This medication can cause hyponatremia, therefore, sodium levels and neurological symptoms should be closely monitored, especially in children, the elderly, or postoperative patients. Due to calcium content, there is a risk of hypercalcemia, so administration should be avoided in patients with a history of hypercalcemia or kidney stones. Fluid overload may occur, so the dosage and rate of administration should be carefully controlled, and fluid balance and electrolyte status should be continuously monitored. Administration is contraindicated or should be done with great caution in specific patient groups such as those with lactic acidosis, fluid overload, hypernatremia, hyperglycemia, and neonates. This medication may interact with various drugs, so the side effects and potential interactions of other drugs administered concurrently must be verified. In pregnant or breastfeeding women, neonates, and elderly patients, the potential risks and benefits of this medication should be carefully considered, with close monitoring of blood sugar and electrolyte status. Prior to administration, disinfect the injection site to prevent infection, warm the medication to body temperature, and adjust the infusion rate slowly. Use immediately after opening and discard any unused medication, and caution is required for continuous infusion to reduce the risk of air embolism. This medication should be stored at room temperature and should not be mixed with formulations containing phosphates or carbonates.

Serious side effects

Urticaria, hypersensitivity reactions including anaphylaxis, dyspnea, severe edema (cerebral edema, pulmonary edema, peripheral edema), hyperkalemia, hyperglycemia, hyponatremic encephalopathy, cardiac arrest

Mild side effects

• Hypertension
• tachycardia
• fever
• vomiting
• chills
• blistering at the injection site
• extravasation
• venous thrombosis
• phlebitis
• pain at the injection site

This medication should be stored in a sealed container to prevent exposure to air or moisture. It is advisable to maintain the storage temperature between 1 and 30 degrees Celsius.

Appearance

Colorless, transparent liquid in a polypropylene, multi-layer film plastic container

Package unit

500mL (bag), 1000mL (bag)